Retest date, expiry date, and the two conventions being confused
A document is only as good as the chain that connects it to the material, and most chains here are two or three links longer than the paperwork admits.
September 2025
Everything filed in September 2025, the month of Volume 2, Number 9. The issue itself — cover, editor’s letter and table of contents — is here.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
VendorInvestigate result on a Changsha orforglipron lot lands 1.6 points below the supplier’s figure
The result is unremarkable. What the report omits is not.
FLOW extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The header, the table and the signature block
The header identifies the batch, the table records the tests, and the footer says who is answerable. Two of the three are usually incomplete.
Why "muscle-sparing" is a marketing term and not a measurement
A tour of the source literatures, with an assessment of how far each legitimately reaches.
The consolidator trading as Meridian Freight Partners closes after 15 years
A proper account of an operation that existed, and of what closing it cost.
France health authority warns on falsified tirzepatide pens
Reported from the analysis, not from a warning notice.
SURPASS-3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A supplier suspends shipping to Turkey after 6 consecutive customs detentions
The route did not close because of a rule about peptides.
The label says four weeks. The clinic says whatever holds.
The published ladder exists because a protocol needed a single number. Practice has never followed it exactly, and the regulatory file never assumed it would.
Background rates, and why they matter for attribution
Pancreatitis is rare, was adjudicated in the outcome programmes, and did not show the imbalance early case reports suggested.
Halvard & Pike Apothecary of Portland, Maine closes after 11 years
A proper account of an operation that existed, and of what closing it cost.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What changed at CPC in September, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The 23-day notice: how a compounding wind-down works in Mexico
The document is four pages. Three of them are about dates.
EGFR, cystatin C, and the check on the check
The reference interval for alanine aminotransferase in most laboratories is derived from a population that included people with undiagnosed fatty liver.
Retest date, expiry date, and the two conventions being confused
A document is only as good as the chain that connects it to the material, and most chains here are two or three links longer than the paperwork admits.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Argentina health authority warns on falsified dulaglutide pens
Reported from the analysis, not from a warning notice.
STEP 2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
What the new Ireland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Fat mass fell more than lean mass. That is the finding, and it is not the headline.
What was pre-specified, what was exploratory, and what was calculated afterwards by people who did not run the trial.
Escalating past the approved maximum, examined honestly
Where the curve flattens, what flattens with it, and what does not.
SURPASS-3 was built to answer the stopping question, and it did
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
Japan caps exenatide prescribing to 16 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
SURPASS-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A supplier suspends shipping to Singapore after 11 consecutive customs detentions
The route did not close because of a rule about peptides.
Oxidation, and the peroxide that came in with the surfactant
Deamidation, oxidation, aggregation and hydrolysis account for nearly all of what happens to a peptide over time. Each has a characteristic residue, a characteristic…
What a 21% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
VendorInvestigate result on a Nantong dulaglutide lot lands 0.9 points below the supplier’s figure
The supplier has not disputed the finding. It has not explained the gap either.
What the new Switzerland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The consolidator trading as Meridian Freight Partners closes after 21 years
A proper account of an operation that existed, and of what closing it cost.
How a claim degrades between the bench and the listing
Lot-level verification with a public report is a real and achievable thing. It exists in this market, on a minority of listings.
The shortage years, and what they taught about interruption
Why the reason for stopping changes what happens afterwards.
STEP 1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Independent analysis puts a CPC cagrilintide lot at 98.4%, against 96.3% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
The quiet end of Halvard & Pike Apothecary of Portland, Maine
A proper account of an operation that existed, and of what closing it cost.
A shortage listing ends. 15 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
Reproducibility, measured rather than assumed
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.